Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-iGAP: Intercalated Gefitinib with Pemetrexed/Cisplatin in Lung Adenocarcinoma
NCT01502202Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2012
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gefitinib in lung adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT01502202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502202.